

研究業績一覽

2025

1. Impact of Sensitive Circulating Tumor DNA Monitoring on CT Scan Intervals During Postoperative Colorectal Cancer Surveillance. Sasaki, Tomoko; Iwaya, Takeshi; Yaegashi, Mizunori; Idogawa, Masashi; Hiraki, Hayato; Abe, Masakazu; Koizumi, Yuka; Sasaki, Noriyuki; Yashima-Abo, Akiko; Fujisawa, Ryosuke; Endo, Fumitaka; Tange, Shoichiro; Otsuka, Koki; Sasaki, Akira; Masuda, Mari; Fujita, Masashi; Nakagawa, Hidewaki; Takahashi, Fumiaki; Sasaki, Yasushi; Tokino, Takashi; Nishizuka, Satoshi S. *Annals of Surgery Open*. 6(1):e549, 2025.
2. Comprehensive Genome Profiling-Initiated Tumor-Informed Circulating Tumor DNA Monitoring for Patients With Advanced Cancer. Sasaki T, Hiraki H, Yashima-Abo A, Nagashima H, Endo F, Yaegashi M, Miura S, Obata K, Yanagawa N, Itamochi H, Shirota H, Iwaya T, Nishizuka SS. *Cancer Sci*. 2025 Jan 5. doi: 10.1111/cas.16446.

2024

1. Sex- and Age-Specific Associations Between Metabolic Syndrome and Future Functional Disability in the Japanese Older Population. Takahashi N, Tsubota-Utsugi M, Takahashi S, Yonekura Y, Ohsawa M, Kuribayashi T, Onoda T, Takanashi N, Sakata K, Yamada T, Ogasawara K, Omama S, Tanaka F, Asahi K, Ishigaki Y, Itabashi R, Itamochi H, Takahashi F, Okayama A, Tanno K. *Inquiry*. 2024; 61: 469580241273103.
2. Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study. Itamochi H, Takeshima N, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Nishio S, Watari H, Yokoyama Y, Kase Y, Sumino S, Kato A, Suri A, Yasuoka T, Takehara K. *J Gynecol Oncol*. 2024; 35: e115.
3. Y-box binding protein 1/cyclin A1 axis specifically promotes cell cycle progression at G2/M phase in ovarian cancer. Murakami Y, Katsuchi D, Matsumoto T, Kanazawa K, Shibata T, Kawahara A, Akiba J, Yanaihara N, Okamoto A, Itamochi H, Sugiyama T, Terada A, Nishio S, Tsuda N, Kato K, Ono M, Kuwano M. *Sci Rep*. 2024; 14: 21701.
4. Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit. Kume K, Iida M, Iwaya T, Yashima-Abo A, Koizumi Y, Endo A, Wade K, Hiraki H, Calvert V, Wulfkühle J, Espina V, Siwak DR, Lu Y, Takemoto K, Suzuki Y, Sasaki Y, Tokino T, Petricoin E 3rd, Liotta LA, Mills GB, Nishizuka SS. *Mol Cell Proteomics*. 2024;23(12):100870.
5. The Clinical Validity of Urinary Pellet DNA Monitoring for the Diagnosis of Recurrent Bladder Cancer. Abe M, Hiraki H, Tsuyukubo T, Ono S, Maekawa S, Tamura D, Yashima-Abo A, Kato R, Fujisawa H, Iwaya T, Park WY, Idogawa M, Tokino T, Obara W, Nishizuka SS. *J Mol Diagn*. 2024;26(4):278-291.
6. Effects of laparoscopic sleeve gastrectomy on nonalcoholic fatty liver disease and TGF- β signaling pathway. Kumagai H, Sasaki A, Umemura A, Kakisaka K, Iwaya T, Nishizuka S. *Endocr J*. 2024 Feb 28;71(2):139-152.
7. Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma. Tamura D, Abe M, Hiraki H, Sasaki N, Yashima-Abo A, Ikarashi D, Kato R, Kato Y, Maekawa S, Kanehira M, Takata R, Maejima K, Sasagawa S, Fujita M, Suzuki Y, Nakagawa H, Iwaya T, Nishizuka SS, Obara W. *Cancer Sci*. 2024;115(2):529-539.
8. Immuno-genomic analysis reveals eosinophilic feature and favorable prognosis of female non-smoking esophageal squamous cell carcinomas. Okawa Y, Sasagawa S, Kato H, Johnson TA, Nagaoka K, Kobayashi Y, Hayashi A, Shibayama T, Maejima K, Tanaka H, Miyano S, Shibahara J, Nishizuka S, Hirano S, Seto Y, Iwaya T, Kakimi K, Yasuda T, Nakagawa H. *Cancer Lett*. 2024 Jan 28;581:216499.

2023

1. Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study. Shirota H, Komine K, Takahashi M, Takahashi S, Miyauchi E, Niizuma H, Tada H, Shimada M, Niihori T, Aoki Y, Sugiyama I, Kawamura M, Yasuda J, Suzuki S, Iwaya T, Saito M, Saito T, Shibata H, Furukawa T, Ishioka C. *Cancer Med.* 2023;12(5):6170-6181.

2022

1. Pembrolizumab Plus Chemotherapy in Japanese Patients With Persistent, Recurrent or Metastatic Cervical Cancer: Results From KEYNOTE-826. Nishio S, Yonemori K, Usami T, Minobe S, Yunokawa M, Iwata T, Okamoto A, Aoki Y, Itamochi H, Takekuma M, Harano K, Yamamoto K, Maruko T, Ugai H, Tekin C, Colombo N, Fujiwara K, Hasegawa K, Ushijima K. *Cancer Sci.* 2022; 113: 3877-3887.
2. PET With ¹¹C-Methyl-L-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma. Beppu T, Iwaya T, Sato Y, Nomura JI, Terasaki K, Sasaki T, Yamada N, Fujiwara S, Sugai T, Ogasawara K. *Clin Nucl Med.* 2022;47(7):569-574.
3. Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy. Koizumi Y, Ahmad S, Ikeda M, Yashima-Abo A, Espina G, Sugimoto R, Sugai T, Iwaya T, Tamura G, Koeda K, Liotta LA, Takahashi F, Nishizuka SS; Northern Japan Gastric Cancer Study Consortium. *J Natl Cancer Inst.* 2022;114(8):1149-1158.
4. Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma. Kogo R, Manako T, Iwaya T, Nishizuka S, Hiraki H, Sasaki Y, Idogawa M, Tokino T, Koide A, Komune N, Yasumatsu R, Nakagawa T. *Cancer Med.* 2022;11(21):3960-3968.

2021

1. Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer. Takehara K, Matsumoto T, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Ushijima K, Watari H, Yokoyama Y, Kase Y, Sumino S, Suri A, Itamochi H, Takeshima N. *J Gynecol Oncol.* 2021; 32: e21.
2. Novel therapeutic strategies for refractory ovarian cancers: Clear cell and mucinous carcinomas. Shoji T, Tatsuki S, Abe M, Tomabechi H, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Baba T, Itamochi H. *Cancers.* 2021; 13: 6120.
3. Primary rhabdomyosarcoma of the ethmoid sinus with orbital extension and metastasis to the pancreatic body. Itamochi H, Ariga H, Shiga K, Uesugi N, Sugai T. *Clin Case Rep.* 2021; 10: e04149.
4. Laparoscopic distal pancreatectomy for metastatic melanoma originating from the choroidal membrane: a case report. Baba S, Akiyama Y, Endo F, Nikai H, Sugimoto R, Umemura A, Katagiri H, Hasegawa Y, Iwaya T, Nitta H, Koeda K, Sugai T, Sasaki A. *Surg Case Rep.* 2021;7(1):268.
5. Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer. Fujisawa R, Iwaya T, Endo F, Idogawa M, Sasaki N, Hiraki H, Tange S, Hirano T, Koizumi Y, Abe M, Takahashi T, Yaegashi M, Akiyama Y, Masuda M, Sasaki A, Takahashi F, Sasaki Y, Tokino T, Nishizuka SS. *Carcinogenesis.* 2021;42(10):1239-1249.
6. Reply. Iwaya T, Nishizuka SS. *Gastroenterology.* 2021;161(1):367-368.
7. Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling. Yaegashi M, Iwaya T, Sasaki N, Fujita M, Ju Z, Siwak D, Hachiya T, Sato K, Endo F, Kimura T, Otsuka K, Sugimoto R, Sugai T, Liotta L, Lu Y, Mills GB, Nakagawa H, Nishizuka SS. *Br J Cancer.* 2021;124(9):1556-1565.
8. Frequent Tumor Burden Monitoring of Esophageal Squamous Cell Carcinoma With Circulating Tumor DNA Using Individually Designed Digital Polymerase Chain Reaction. Iwaya T, Endo F, Takahashi F, Tokino T, Sasaki Y, Nishizuka SS. *Gastroenterology.* 2021;160(1):463-465.

9. Efficacy of enhanced prehabilitation for patients with esophageal cancer undergoing esophagectomy. Akiyama Y, Sasaki A, Fujii Y, Fujisawa R, Sasaki N, Nikai H, Endo F, Baba S, Hasegawa Y, Kimura T, Takahara T, Nitta H, Otsuka K, Koeda K, Nishimura Y, Iwaya T. *Esophagus*. 2021;18(1):56-64.

2020

1. Development of Potent Forchlorfenuron Analogs and Their Cytotoxic Effect in Cancer Cell Lines. Kim KK, Singh RK, Khazan N, Kodza A, Singh NA, Jones A, Sivagnanalingam U, Towner M, Itamochi H, Turner R, Moore RG. *Sci Rep*. 2020; 10: 3241.
2. Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C. Kolendowski B, Valdes YR, Hirte H, Itamochi H, Lee W, Carey M, Shepherd TG, DiMattia GE. *Cells*. 2020; 9: 2408.
3. Genome-wide analysis of microRNA to evaluate prognostic markers in isolated cancer glands and surrounding stroma in high-grade serous ovarian carcinoma. Sato C, Osakabe M, Nagasawa T, Suzuki H, Itamochi H, Baba T, Sugai T. *Oncol Lett*. 2020; 20: 338.
4. Primary ovarian serous psammocarcinoma-a case report with mini literature review. Fukagawa Y, Itamochi H, Sato C, Tomabechi H, Nagasawa T, Kagabu M, Shoji T, Sugai T, Baba T. *Obstet Gynecol Int J*. 2020; 11: 192-195.
5. Rapid progression of recurrent disease in a patient with renal cell carcinoma with vaginal metastasis. Hisano M, Kato R, Itamochi H, Matsuura T, Maekawa S, Kato Y, Kanehira M, Takata R, Baba T, Obara W. *IJU Case Reports*. 2020; 3: 185-188.
6. Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA. Sasaki N, Iwaya T, Chiba T, Fujita M, Ju Z, Endo F, Yaegashi M, Hachiya T, Sugimoto R, Sugai T, Siwak DR, Liotta LA, Lu Y, Mills GB, Nakagawa H, Nishizuka SS. *PLoS One*. 2020 7;15(10):e0239966.
7. Surgical outcomes of 118 complex laparoscopic liver resections: a single- center experience. Hasegawa Y, Nitta H, Takahara T, Katagiri H, Kanno S, Umemura A, Akiyama Y, Iwaya T, Otsuka K, Sasaki A. *J Hepatobiliary Pancreat Sci*. 2020;27(12):942-949.
8. Feasibility of totally laparoscopic pylorus-preserving gastrectomy with intracorporeal gastro-gastrostomy for early gastric cancer: a retrospective cohort study. Akiyama Y, Sasaki A, Iwaya T, Fujisawa R, Sasaki N, Nikai H, Endo F, Baba S, Hasegawa Y, Kimura T, Takahara T, Nitta H, Otsuka K, Koeda K. *World J Surg Oncol*. 2020 Jul 16;18(1):170.